1. Home
  2. UVV vs CVAC Comparison

UVV vs CVAC Comparison

Compare UVV & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

HOLD

Current Price

$53.17

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo CureVac N.V.

CVAC

CureVac N.V.

HOLD

Current Price

$4.32

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVV
CVAC
Founded
1886
2000
Country
United States
Germany
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
UVV
CVAC
Price
$53.17
$4.32
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$6.83
AVG Volume (30 Days)
160.0K
1.7M
Earning Date
02-09-2026
11-24-2025
Dividend Yield
6.17%
N/A
EPS Growth
N/A
94.02
EPS
4.44
0.94
Revenue
$2,987,411,000.00
$83,000,117.00
Revenue This Year
$3.21
N/A
Revenue Next Year
$1.02
$23.71
P/E Ratio
$11.98
$4.59
Revenue Growth
3.01
N/A
52 Week Low
$49.40
$2.48
52 Week High
$67.33
$5.72

Technical Indicators

Market Signals
Indicator
UVV
CVAC
Relative Strength Index (RSI) 47.69 31.39
Support Level $52.93 $4.00
Resistance Level $55.14 $4.36
Average True Range (ATR) 0.81 0.16
MACD -0.07 -0.06
Stochastic Oscillator 36.09 22.51

Price Performance

Historical Comparison
UVV
CVAC

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About CVAC CureVac N.V.

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Share on Social Networks: